| HIV Infections
Reyataz vs Cabenuva
Side-by-side clinical, coverage, and cost comparison for hiv infections.Deep comparison between: Reyataz vs Cabenuva with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsCabenuva has a higher rate of injection site reactions vs Reyataz based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Cabenuva but not Reyataz, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Reyataz
Cabenuva
At A Glance
Oral
Once daily
HIV-1 protease inhibitor
IM injection (gluteal)
Every 4 weeks or every 8 weeks
INSTI + NNRTI combination
Indications
- HIV Infections
- HIV Infections
Dosing
HIV Infections (treatment-naive adults) 300 mg once daily with ritonavir 100 mg once daily with food, or 400 mg once daily with food if unable to tolerate ritonavir
HIV Infections (treatment-experienced adults) 300 mg once daily with ritonavir 100 mg once daily with food; 400 mg once daily with ritonavir 100 mg once daily if taken with both tenofovir DF and H2-receptor antagonist
HIV Infections (pediatric patients 6 to less than 18 years, 15 to less than 35 kg) 200 mg once daily with ritonavir 100 mg once daily with food
HIV Infections (pediatric patients at least 35 kg) 300 mg once daily with ritonavir 100 mg once daily with food
HIV Infections (pediatric patients at least 3 months, 5 to less than 15 kg) 200 mg oral powder once daily with ritonavir 80 mg once daily with food
HIV Infections (pregnant patients) 300 mg once daily with ritonavir 100 mg once daily with food; 400 mg once daily with ritonavir 100 mg once daily during second or third trimester when coadministered with either H2-receptor antagonist or tenofovir DF
HIV Infections (Monthly Dosing) Initiation: cabotegravir 600 mg IM + rilpivirine 900 mg IM on last day of current antiretroviral therapy or oral lead-in; Continuation: cabotegravir 400 mg IM + rilpivirine 600 mg IM every month thereafter. Separate gluteal injection sites required.
HIV Infections (Every 2-Month Dosing) Initiation: cabotegravir 600 mg IM + rilpivirine 900 mg IM on last day of current antiretroviral therapy or oral lead-in, repeated 1 month later; Continuation: cabotegravir 600 mg IM + rilpivirine 900 mg IM every 2 months thereafter. Separate gluteal injection sites required.
Contraindications
- Previously demonstrated clinically significant hypersensitivity (eg, Stevens-Johnson syndrome, erythema multiforme, toxic skin eruptions) to any component
- Coadministration with drugs highly dependent on CYP3A or UGT1A1 for clearance where elevated plasma concentrations are associated with serious or life-threatening events (alfuzosin, cisapride, pimozide, orally administered midazolam, triazolam, ergot derivatives, lovastatin, simvastatin, lomitapide, sildenafil for pulmonary arterial hypertension, indinavir, irinotecan, lurasidone when boosted with ritonavir, apalutamide, encorafenib, ivosidenib, elbasvir/grazoprevir, glecaprevir/pibrentasvir)
- Coadministration with strong CYP3A inducers (rifampin, St. John's wort, carbamazepine, phenobarbital, phenytoin, nevirapine)
- Previous hypersensitivity reaction to cabotegravir or rilpivirine
- Carbamazepine, oxcarbazepine, phenobarbital, phenytoin (anticonvulsants)
- Rifabutin, rifampin, rifapentine (antimycobacterials)
- Dexamethasone (systemic, more than single dose)
- St. John's wort (Hypericum perforatum)
Adverse Reactions
Most common (>=2%) Nausea, jaundice/scleral icterus, rash, headache, insomnia, dizziness, vomiting, abdominal pain, diarrhea, fever, myalgia, depression, peripheral neurologic symptoms
Serious Cardiac conduction abnormalities (PR interval prolongation, second-degree AV block, third-degree AV block), chronic kidney disease, nephrolithiasis, cholelithiasis
Postmarketing Edema, QTc prolongation, left bundle branch block, pancreatitis, hepatic function abnormalities, cholecystitis, cholestasis, diabetes mellitus, hyperglycemia, arthralgia, interstitial nephritis, granulomatous interstitial nephritis, alopecia, maculopapular rash, pruritus, angioedema
Most common (>=2%) Injection site reactions (pain/discomfort, nodules, induration, swelling, erythema, pruritus, bruising/discoloration, warmth, hematoma), pyrexia, fatigue, headache, musculoskeletal pain, nausea, sleep disorders, dizziness, rash
Serious Hypersensitivity reactions including angioedema and urticaria, hepatotoxicity, depression and suicidal ideation/attempt, severe skin reactions including DRESS and Stevens-Johnson syndrome/toxic epidermal necrolysis
Postmarketing Hypersensitivity reactions, nephrotic syndrome, severe skin and hypersensitivity reactions including DRESS, Stevens-Johnson syndrome, toxic epidermal necrolysis
Pharmacology
Atazanavir is an azapeptide HIV-1 protease inhibitor that selectively inhibits virus-specific processing of viral Gag and Gag-Pol polyproteins in HIV-1-infected cells, preventing formation of mature virions.
Cabotegravir inhibits HIV integrase by binding to the active site and blocking the strand transfer step essential for HIV replication. Rilpivirine is an NNRTI that inhibits HIV-1 replication by non-competitive inhibition of HIV-1 reverse transcriptase.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Reyataz
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (11/12)
Cabenuva
- Covered on 5 commercial plans
- PA (1/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Reyataz
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (4/8)
Cabenuva
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Reyataz
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Cabenuva
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableGood Days: HIV, AIDS Treatment & Prevention
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$0/fillfill
Cabenuva Patient Savings ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
ReyatazView full Reyataz profile
CabenuvaView full Cabenuva profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.